• Supported downstream process development and commercialization activities for late-stage and commercial biologic drug substance manufacturing processes• Collaborated with upstream, process analytics, and Merck Research Laboratories, and drug product teams to accelerate the commercialization of pipeline molecules and enable end-to-end control strategies• Developed robust downstream process trains, process intensification, process characterization, technology transfer, application of Quality by Design principles and process validation• Assisted and mentored junior staff on the design of experiments and analysis of experimental data• Responsible for process development, characterization, tech transfer and process validation, and INDdocumentation authoring of a high concentration formulation for a subcutaneous image• Led a matrix team for the downstream process for two programs one of which have had 100% successful PPQ,and the other is ongoing• Responsible for convincing internal and external partners of challenging topics to ensure successful tech transfers• SME for a department of over 90 individuals for all materials related to tangential flow filtration• Solved challenging mixing programs and to develop a robust tool set, using process models in tandem with monte carlo simulations and sensitivity analysis to enable risk-based facility fits and reduction of CoGs by nearly 40%

• I lead a team of 8 research scientists in the development of a cell-free metabolic platform for sequestering industrially produced CO2 which has advanced to the Round 2 of the $20M NRG COSIA Carbon XPRIZE competition. • I authored multiple successfully funded grants which garnered more than $550K. • Through the implementation of DoE and multivariate analysis, I have developed and scaled-up purification procedures (mg to g) for production of 20+ enzymes using chromatographic methods including IEX, HIC, SEC and IMAC.• Developed multiple 2-step tandem purification methods using AKTA Pure 25 and Avant 150. These protocols have reduced operator error, increased throughput with higher consistency across batches.• Designed and optimized several novel high-throughput assays for characterization of enzymes which increased productivity and reduced sample usage by 100-fold.• Engineered an artificial organelle that combines the metabolisms of Photosystem II and Respiratory Complex I for the reduction of NAD+ using light as a source of energy and producing only oxygen as a by-product.• I routinely use JMP and Matlab to design experiments and analyze their results. • I mentored a team of 6 undergraduate research students that competed in the 2016 International Genetically Engineered Machine (iGEM) competition and were award a Bronze Medal.

• My role was to design and support studies and identify root-causes for process deviations. I also was responsible for authoring technical protocols and reports for FDA change control submissions and validating new equipment. • I identified a critical flaw in materials manufactured by external vendors and successfully established new specifications across multiple vendors. I successfully lead an accelerated effort to validate the new materials avoiding the stoppage of filling operations across 6 lines. • Worked closely with Quality and Operations to execute change controls and process simulations. • Mentored a summer engineering intern.

• I supported the development of siRNA delivery vehicle formulations, target validation, and manufacturing processes, including executing DoE for formulation development, lab-scale manufacture, process scale-up and tech transfer to GMP facilities for clinical trial material production.• I was responsible for optimization and troubleshooting downstream process operations including tangential flow filtration, chromatographic separations, sterile filtration. • Developed an automated manufacturing process which reduced human error related deviations and operator time.• Collaborated with internal groups to meet production needs for target validation studies.• I was responsible for organizing batch processing plans, calculations, and schedules.

• Team leader for federal Qualifying Therapeutic Discovery Program • Authored grants in which 4 out of 5 received maximum allowable rewards

• Synthesized and developed Multifunctional Albumin Nanoparticles for tissue targeted imaging and cancer therapeutic delivery with increased tumor penetration• Maintained and harvested multiple mammalian cell lines (e.g. melanocyte, glioblastoma, CHO cells)

• Successfully developed a biologically based carbon-fixation platform• Recognized for involvement in research with the following publication: Wendell, D. et al. “Artificial Photosynthesis in Ranaspumin-2 Based Form” Nano Letters, 2010, 10(9), 3231-3246.